This indicates that CLL cells may re-wire and can overcome the effects of fludarabine by simply restoring the MYC-specific transcriptional reprogramming and that the irreversible change in the cellular program, by brief suppression of MYC [70] may not be applicable to CLL patients. The gene discussed is MYC; the disease is B-cell chronic lymphocytic leukemia.